Protocol Details

Eligibility Screening for the NIH Intramural Research Program Clinical Protocols

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number	01-C-0129
Sponsoring Institute	National Cancer Institute (NCI)
Recruitment Detail	Type: No longer recruiting/follow-up only Gender: Male & Female Min Age: 1 mo Max Age: N/A
Referral Letter Required	No
Population Exclusion(s)	None
Keywords	Screening; Cancer; HIV Infection; Scans; Laboratory Tests
Recruitment Keyword(s)	HIV; Skin Disorders; Cancer; Screening
Condition(s)	Breast Cancer; Prostate Cancer; Lung Cancer; Sarcoma; Melanoma
Investigational Drug(s)	None
Investigational Device(s)	None
Intervention(s)	None
Supporting Site	National Cancer Institute

The purpose of this protocol is to provide patients with adequate informed consent to understand that screening tests with minimal health risk will be performed to evaluate their eligibility for a research study. The protocol makes it clear that patients initial visit to the intramural clinical program may include screening studies that are not medically necessary for disease management, but are done purely for research purposes.

Patients with a known or suspected diagnosis of cancer, HIV infection, skin disorder or immunodeficiency who are being considered for enrollment in a National Cancer Institute intramural clinical research protocol will participate in this consent protocol. It informs patients of screening tests and procedures involving minimal risk that are done for research purposes only, including blood tests, electrocardiogram, standard X-rays (e.g., chest X-ray), bone films, computed tomography (CT), magnetic resonance imaging (MRI), and nuclear medicine studies. It explains that other eligibility screens that are more invasive and involve greater risk, such as a biopsy, will require separate consent.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

-Patients and healthy volunteers who are being evaluated for protocols within the NIH Intramural Research Program (IRP). Note: Participants must be > 1 month of age.

-All patients or their parent/guardians or Legally Authorized Representative (LAR) must sign a document of informed consent indicating their understanding of the research nature and the risks of the procedures that will be performed to assess eligibility for research protocols. NOTE: It is expected that healthy adult volunteers have the capacity to consent (i.e., a LAR may not be used).

EXCLUSION CRITERIA:

None

--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator	Referral Contact	For more information:
James L. Gulley, M.D. National Cancer Institute (NCI) NIHBC 10 - CLINICAL CENTER BG RM 13N240C 10 CENTER DR BETHESDA MD 20892 (301) 480-7164 gulleyj@mail.nih.gov	James L. Gulley, M.D. National Cancer Institute (NCI) NIHBC 10 - CLINICAL CENTER BG RM 13N240C 10 CENTER DR BETHESDA MD 20892 (301) 480-7164 gulleyj@mail.nih.gov	NCI Referral Office National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office 1-888-NCI-1937 ncimo_referrals@mail.nih.gov

Clinical Trials Number:

NCT00026754

--Back to Top--